Reversible posterior leukoencephalopathy syndrome induced by apatinib: a case report and literature review

• Main Authors: Li XT, Chai J, Wang Z, Lu L, Zhao QY, Zhou J, Ju F
• Format: Article
• Language: English
• Published: Dove Medical Press 2018-07-01
• Series: OncoTargets and Therapy
• Subjects: reversible posterior leukoencephalopathy syndrome; apatinib; antiangiogenesis; targeted therapy;
• Online Access: https://www.dovepress.com/reversible-posterior-leukoencephalopathy-syndrome-induced-by-apatinib--peer-reviewed-article-OTT

Xutong Li,1 Jie Chai,1 Zhi Wang,2 Lin Lu,1 Qingye Zhao,1 Jie Zhou,1 Fang Ju1 1Department of Oncology, Second Affiliated Hospital, Qingdao University, Qingdao, Shandong 266042, People’s Republic of China; 2Department of MRI, Second Affiliated Hospital, Qingdao University, Qingdao, Shandong 266042, People’s Republic of China Abstract: Reversible posterior leukoencephalopathy syndrome (RPLS) is a rare clinical-radiologic syndrome. There are reports that RPLS may be associated with cancer therapy including some chemotherapy drugs and antiangiogenic drugs. This paper reported a case of RPLS induced by apatinib, a vascular endothelial growth factor receptor 2 (VEGFR-2) tyrosine kinase inhibitor. A 47-year-old cervical cancer patient was administered apatinib, and 3 months later, headache, dizziness, blurred vision, and hypertension appeared. She was diagnosed with RPLS by nuclear magnetic resonance imaging (MRI). After apatinib discontinuation and normotensive treatment, her symptoms completely reversed. Antiangiogenic drugs potentially damage the balance of the blood–brain barrier by directly injuring vascular endothelial cells, resulting in the occurrence of RPLS. This case is the first report of RPLS induced by apatinib. Keywords: reversible posterior leukoencephalopathy syndrome, apatinib, antiangiogenesis, targeted therapy